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Objective. Anti–cyclic citrullinated peptide (anti-
CCP) antibodies are a stronger predictor of the severity
of rheumatoid arthritis than is rheumatoid factor (RF).
Their role in predicting outcome in unselected patients
with new-onset inflammatory polyarthritis (IP) has not
been examined. The aims of this study were to examine
the role of baseline RF and anti-CCP antibodies in
determining the likelihood of patients having erosions
at presentation or in predicting future radiologic dam-
age, and to determine whether anti-CCP antibodies or
RF is sufficiently robust to be clinically useful in guiding
treatment decisions in early IP.
Methods. Patients were recruited from the Nor-
folk Arthritis Register. Logistic regression models were
fitted to test the ability of anti-CCP antibodies and RF
to predict erosions. Further models were investigated to
examine the role of anti-CCP antibodies in patients
stratified by RF status.
Results. The presence of anti-CCP antibodies at
baseline was strongly associated with both prevalent
erosions (odds ratio [OR] 2.53 [95% confidence interval
(95% CI) 1.48–4.30]) and developing erosions at 5 years
(OR 10.2 [95% CI 6.2–16.9]). These ORs were higher
than those for RF (OR 1.63 [95% CI 0.94–2.82] and OR
3.4 [95% CI 2.2–5.2], respectively). The likelihood ratio
(LR) for the prediction of prevalent erosions and ero-
sions at 5 years was highest in the RFsubgroup (LR
2.2 and 5.8, respectively). However, 27% of anti-
CCPpatients had developed erosions by 5 years.
Conclusion. Despite their strong association with
the presence, development, and extent of erosions, anti-
CCP antibodies alone are not a sufficiently accurate
measure upon which to base clinical treatment deci-
sions. Knowledge of anti-CCP antibody status is most
informative in RFnegative patients.
There is considerable evidence of the benefit of
early treatment with disease-modifying antirheumatic
drugs (DMARDs) in patients with rheumatoid arthritis
(RA). These studies have shown that there is a window
of opportunity early in the disease course during which
DMARDs have the greatest effect in altering disease
progression, as measured by the development of radio-
logic erosions (1,2). The identification of a marker at the
onset of disease that could reliably predict which pa-
tients will or, perhaps more importantly, will not develop
erosions would be a major clinical advance because the
latter group could be spared potentially toxic therapies,
while the former group may be targeted for combination
or biologic therapy. There have been several prospective
studies that have examined the relative role of different
clinical and laboratory predictors. The presence of rheu-
matoid factor (RF) and of shared epitope (SE) alleles of
the HLA–DRB1 gene has been consistently associated
with an adverse outcome (3–5).
More recently, studies have has focused on the
role of antibodies that recognize cyclic citrullinated
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2929peptides (anti–citrullinated protein antibodies
[ACPAs]) (6). ACPAs, as measured by anti–CCP-2
enzyme-linked immunosorbent assays (ELISAs), are
highly specific and reasonably sensitive for diagnosing
RA (7), although RF may still be present in persons with
RA who are negative for anti-CCP antibodies (8).
Cross-sectional surveys of prevalent RA cases have also
shown that both RF and anti-CCP antibodies are asso-
ciated with radiographic severity (6,9–11), but recent
studies suggest that their effects are not completely
overlapping (10). Prospective studies have confirmed
the association of anti-CCP antibodies with worsening
radiographic outcome in patients with RA at baseline
(6,12–18). It has also been shown that the presence of
these antibodies in patients presenting with undifferen-
tiated inflammatory arthritis is associated with an in-
creased likelihood of being classified as having RA (13).
A limitation of many previous studies has been
the restriction of the investigation to patients with
definite RA. In this group, it is difficult to evaluate
erosions as an outcome since erosions are one of the
criteria used for classification of RA. We have argued
previously that an unselected series of patients with
inflammatory polyarthritis (IP) would provide a more
representative cohort in which to develop prognostic
models because the American College of Rheumatology
(ACR; formerly, the American Rheumatism Associa-
tion) classification criteria for RA (19) do not perform
well in early disease (20). Furthermore, rheumatologists
increasingly want to make therapeutic decisions before
patients satisfy the ACR criteria, because there is con-
siderable evidence to suggest that it is in the early stages
of the disease that treatment is most likely to affect
outcome (21).
In our previous study of primary care–based
unselected series of patients with IP presenting between
1990 and 1994, we reported that RF was the most
important baseline predictor of erosive disease at 5 years
(22), but we have not examined the role of anti-CCP
antibodies. The aim of this study was to compare the
roles of RF and anti-CCP antibody status in determining
the likelihood of having erosions at presentation and in
predicting future radiologic damage. We also deter-
mined whether anti-CCP antibody status, either alone or
in combination with RF, is sufficiently robust to be
useful in guiding clinical treatment decisions.
PATIENTS AND METHODS
Study protocol. Subjects were recruited from the Nor-
folk Arthritis Register (NOAR), a primary care–based incep-
tion cohort of patients with IP. Details of NOAR have been
published previously (23). Briefly, patients with swelling in 2 or
more joints that lasted 4 weeks or longer were referred to
NOAR and were assessed by a trained metrologist within 2
weeks of referral using a standardized approach. Data gath-
ered included joint counts for swelling and tenderness and
responses on the Health Assessment Questionnaire (24).
Blood was obtained for serum analysis (initially for RF, but
C-reactive protein and anti-CCP testing have been introduced
more recently) and DNA extraction.
Radiographs of the hands and feet were requested for
each consenting patient and were scored using the Larsen scale
(25). All radiographs were scored by 2 observers, with a third
observer arbitrating in case of disagreement (MB, DS, and
AB). Details of the radiographic scoring process used in
NOAR have been published elsewhere (22). Briefly, a Larsen
score of 2 in any joint indicated the presence of erosions.
Joints assessed include all proximal interphalangeal joints, the
interphalangeal joint of the thumbs, all metacarpophalangeal
joints, both wrists, and the second through fifth metatarsopha-
langeal joints in both feet. A weighting factor of 5 was applied
to each wrist. The total possible score was 190.
Criteria for ascertainment of radiographs have
changed over the time period that patients have been re-
cruited to NOAR. Two cohorts of patients were included in the
current study. The prospective cohort was composed of 427
consecutive unselected patients recruited between 1990 and
1994 who had both a baseline serum sample and a radiograph
at 5 years available for analysis. These patients did not have a
baseline radiograph performed. A more recently recruited
cross-sectional cohort was studied based on 254 consecutive
patients recruited after January 1, 2000 who had a baseline
radiograph performed.
Serum testing. RF was measured using a latex
method, and a titer of 1:40 was regarded as positive. Anti-
CCP testing was performed using the Axis-Shield DIASTAT
kit according to the manufacturer’s instructions (Axis-Shield,
Dundee, UK), using the recommended cutoff of 5 units/ml as
positive.
Statistical analysis. The baseline characteristics of the
cohorts were compared, stratified according to their anti-CCP
and RF status. For the prospective cohort, erosion status and
Larsen score at 5 years were also analyzed in this way.
Categorical values were compared using the chi-square test,
and continuous variables were compared using the Mann-
Whitney U test.
We constructed 2  2 tables examining the prevalence
of erosions in the various groups, depending on their anti-CCP
and RF status alone and in combination. Odds ratios (ORs)
and 95% confidence intervals (95% CIs) were calculated using
Stata software (StataCorp, College Station, TX). The absolute
values of ELISA-measured anti-CCP antibody levels were also
used as a continuous variable to determine their association
with the development of erosions at 5 years using a receiver
operating curve (ROC) analysis.
Four groups were identified within each cohort, de-
pending on their autoantibody profile: patients who were
both anti-CCP and RF, patients who were RF and
anti-CCP, patients who were RF and anti-CCP, and
those who were both anti-CCP and RF. Larsen scores
for subjects with erosions in the 4 groups were ascertained
and compared using the Mann-Whitney U test. Sensitivity,
2930 BUKHARI ET ALspecificity, and likelihood ratios (LRs) were calculated
for each of these groups using the “diagt” command in Stata.
All analyses were repeated, adjusting for the use of
DMARDs or steroids at 5 years. P values less than 0.05 were
considered significant.
RESULTS
Clinical characteristics at baseline. The baseline
characteristics of each cohort are shown in Table 1. At 5
years, 311 subjects in the prospective cohort (72.8%) had
Table 1. Patient characteristics at baseline and at 5 years, in patients with available data*
Cross-sectional cohort
(n  254)
Prospective cohort
(n  427)
Baseline
Female, no. (%) 173 (68.1) 283 (66.3)
Age at symptom onset, median (IQR) years 59.2 (48.4–70.6) 53.3 (42.6–70.5)
HAQ score, median (IQR) 0.88 (0.25–1.50) 0.75 (0.25–1.38)
RF, no. (%) 71 (28.0) 113 (26.5)
Anti-CCP, no. (%) 88 (34.6) 125 (29.3)
No. of tender joints, median (IQR) 3 (1–8) 8 (3–16)
No. of swollen joints, median (IQR) 3 (1–8) 6 (2–14)
Shared epitope alleles, no. (%)
0 79 (48.5) 155 (39.4)
1 63 (38.6) 181 (46.1)
2 21 (12.9) 57 (14.5)
5 years
No. of tender joints, median (IQR) – 0 (0–4)
No. of swollen joints, median (IQR) – 0 (0–2)
HAQ score, median (IQR) – 0.75 (0.25–1.5)
Treated with DMARD or steroid by 5 years, no. (%) – 257 (60.2)
Satisfied ACR criteria for RA by year 5, no. (%) – 311 (72.8)
Symptom duration at baseline, median (IQR) months 5 (3–10) 5 (2–12)
* IQR  interquartile range; HAQ  Health Assessment Questionnaire; RF  rheumatoid factor;
anti-CCP  anti–cyclic citrullinated peptide antibody; DMARD  disease-modifying antirheumatic drug;
ACR  American College of Rheumatology; RA  rheumatoid arthritis.
Table 2. Clinical characteristics of the patients at baseline, according to the presence and absence of anti-CCP and RF at baseline*
Anti-CCP Anti-CCP RF RF
Cross-sectional cohort
No. of subjects 88 166 71 183
Female, no. (%) 64 (72.7) 109 (65.7) 50 (70.4) 90 (67.2)
Age at symptom onset, median (IQR) years 60.7 (52.2–71.4) 58.5 (45.0–71.1) 62.7 (48.9–72.0) 58.5 (47.7–71.1)
HAQ score at baseline, median (IQR) 1.0 (0.38–1.75) 0.75 (0.25–1.50)† 1 (0.38–1.5) 0.88 (0.25–1.50)
Erosions at baseline, no. (%) 55 (62.5) 66 (39.8)‡ 40 (56.3) 81 (44.3)
Larsen score at baseline, median (IQR) 6.5 (1–14.5) 2 (0–10)§ 5 (0–15) 3 (0–12)
Prospective cohort
No. of subjects 125 302 112 308
Female, no. (%) 77 (61.6) 206 (68.2) 71 (62.8) 212 (67.5)
Age at symptom onset, median (IQR) years 55.7 (48.4–64.0) 51.7 (40.8–62.7) 55.7 (46.8–64.0) 52.4 (42.1–62.4)
HAQ score, median (IQR) 0.88 (0.38–1.62) 0.63 (0.25–1.25)¶ 0.75 (0.38–1.50) 0.75 (0.25–1.25)#
Erosions at 5 years, no. (%) 99 (79.2) 82 (27.2)** 74 (65.5) 107 (34.1)††
Larsen score at 5 years, median (IQR) 29 (12–44) 2 (0–10)¶ 17 (3–41) 4 (0–14)¶
Treated with DMARD or steroid by 5 years, no. (%) 119 (95.2) 138 (45.7)‡‡ 91 (80.5) 166 (52.9)§§
* See Table 1 for definitions.
† P  0.04 versus anti-CCP group.
‡ P  0.001 versus anti-CCP group.
§ P  0.02 versus anti-CCP group.
¶ P  1  10
4 versus anti-CCP group.
# P  0.01 versus RF group.
** P  4  10
23 versus anti-CCP group.
†† P  6.7  10
9 versus RF group.
‡‡ P  1.9  10
21 versus anti-CCP group.
§§ P  2.6  10
7 versus RF group.
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studies. In the cross-sectional cohort, 88 (34.6%) were
anti-CCP, 71 (28.0%) were RF, and 50 (19.7%) were
anti-CCP and RF, while in the prospective cohort,
125 (29.3%) were anti-CCP, 113 (26.5%) were RF,
and 80 (18.7%) were anti-CCP and RF. The pres-
ence of anti-CCP antibodies was highly, but not per-
fectly, correlated with the presence of RF. For example,
the kappa statistic was 0.47 in the cross-sectional cohort
(P  0.001) and 0.59 in the prospective cohort (P 
0.001). The presence of anti-CCP antibodies, but not
RF, at baseline was associated with prevalent erosions,
and both were associated with erosions and was the
presence of Larsen score by 5 years (Table 2).
The presence of anti-CCP antibodies at baseline
was a more powerful predictor of both prevalent ero-
sions (OR 2.53 [95% CI 1.48–4.30]) and developing
erosions by 5 years (OR 10.2 [95% CI 6.2–16.9]) than
was the presence of RF (OR 1.63 [95% CI 0.94–2.82]
and 3.4 [2.2–5.2], respectively) (Table 3). Modeling the
role of anti-CCP antibodies stratified by RF status
showed that anti-CCP antibodies perform equally well in
predicting erosions in RF and RF patients, and the
presence of both autoantibodies did not yield signifi-
cantly higher odds of erosions (either prevalent or at 5
years) than did anti-CCP alone (OR for erosions at 5
years in anti–CCP patients 10.2 [95% CI 6.2–16.9]; OR
for erosions at 5 years in anti-CCP,R F  patients 11.6
[95% CI 4.5–29.9]).
Larsen scores were higher in anti-CCP patients
than in anti-CCP patients, both at baseline and at 5
years (Table 2). Patients with erosions who were anti-
CCP at baseline had higher Larsen scores at 5 years
(median 36, interquartile range [IQR] 20–48) than did
anti-CCP patients (median 16 [IQR 10–27]), although
no difference in their baseline demographic features
were noted. The median Larsen score at 5 years, but not
at baseline, was higher in the anti-CCP patients,
regardless of their RF status (Figures 1 and 2).
Development of erosions. At 5 years, erosions
had developed in 81% of RF, anti-CCP patients and
27% of RF, anti-CCP patients. The titers of anti-
CCP antibodies were higher in RF (median 25.9 [95%
CI 1.0–74.3]) than in RF (median 0.74 [95% CI
0.48–1.26]) patients. The sensitivity and specificity of the
models derived from Table 3 showed that both RF and
anti-CCP antibodies were stronger predictors of ero-
sions at 5 years than at presentation (Table 4). The
specificities for predicting erosions at 5 years were
similar for RF and anti-CCP antibodies, but the latter
were more sensitive. Interestingly, the presence of anti-
CCP antibodies had the highest LR for erosions,
whether at baseline or at 5 years, in RF patients.
However, the area under the curve in the ROC analysis
was higher in RF, anti-CCP subjects than in RF,
anti-CCP subjects (0.78 [95% CI 0.69–0.87] and 0.66
[95% CI 0.59–0.73], respectively), suggesting that anti-
CCP is a better predictor of erosions at 5 years in the
presence of RF positivity.
The ROC analysis was also used to determine
whether there is a cutoff of anti-CCP antibody values at
which erosions at 5 years can be accurately predicted.
The peak of the ROC curve occurred at an anti-CCP
antibody value of 2.4 when the whole data set was
Table 3. Prevalence and odds of erosions in patients at presentation and at 5 years, by autoantibody status at baseline*
Antibody status at baseline
OR (95% CI)
Present Absent
No. (%)
with
erosions
No. (%)
without
erosions
No. (%)
with
erosions
No. (%)
without
erosions
Cross-sectional cohort (at presentation)
All anti-CCP 55 (63) 33 (37) 66 (40) 100 (60) 2.53 (1.48–4.30)
Anti-CCP,R F  24 (63) 14 (37) 57 (39) 88 (61) 2.65 (1.27–5.54)
Anti-CCP,R F  31 (62) 19 (38) 9 (43) 12 (57) 2.18 (0.77–6.13)
All RF 40 (56) 31 (44) 81 (44) 102 (56) 1.63 (0.94–2.82)
RF, anti-CCP 9 (43) 12 (57) 57 (39) 88 (61) 1.16 (0.46–2.92)
RF, anti-CCP 31 (62) 19 (38) 24 (63) 14 (37) 0.95 (0.40–2.28)
Prospective cohort (at 5 years)
All anti-CCP 99 (79) 26 (21) 82 (27) 220 (73) 10.2 (6.2–16.9)
Anti-CCP,R F  34 (76) 11 (24) 73 (27) 196 (73) 8.3 (4.0–17.2)
Anti-CCP,R F  65 (81) 15 (19) 9 (27) 24 (73) 11.6 (4.5–29.9)
All RF 83 (63) 48 (37) 122 (34) 240 (66) 3.4 (2.2–5.2)
RF, anti-CCP 9 (27) 24 (73) 73 (27) 196 (73) 1.01 (0.45–2.27)
RF, anti-CCP 65 (81) 15 (19) 34 (76) 11 (24) 1.40 (0.58–3.39)
*O R odds ratio; 95% CI  95% confidence interval (see Table 1 for other definitions).
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RF subjects, indicating that, even at low titers, the
presence of the antibody is associated with erosive
change.
Logistic regression analyses were repeated using
DMARDs or steroids at 5 years as a cofactor, but in no
situation did this correction alter the conclusions, al-
though it did attenuate the effects seen. For example,
the OR of developing erosions at 5 years in the presence
of anti-CCP antibodies at baseline was reduced to 7.1
Figure 1. Distribution of Larsen scores at baseline in all subjects (A) and in subjects with
prevalent erosions (B), according to baseline antibody status in the cross-sectional cohort. Values
are presented as box and whisker plots, where the boxes represent the interquartile range, the lines
within the boxes represent the median Larsen score, the whiskers represent the range from the
smallest to the largest score, and the circles represent outliers. No significant differences between
the groups were noted. 1 represents subjects who were RF and anti-CCP (P  0.07 versus
subjects who were RF and anti-CCP in the total group and P  0.70 versus subjects who were
RF and anti-CCP in the group with erosions). 2 represents subjects who were RF and
anti-CCP (P  0.06 versus subjects who were RF and anti-CCP in the total group and P 
0.49 versus subjects who were RF and anti-CCP in the group with erosions). 3 represents
subjects who were RF and anti-CCP (P  0.90 versus subjects who were RF and anti-CCP
in the total group and P  0.34 versus subjects who were RF and anti-CCP in the group with
erosions). 4 represents subjects who were RF and anti-CCP (referent).
Figure 2. Distribution of Larsen scores at 5 years in all subjects (A) and in subjects with erosions
(B), according to baseline antibody status in the prospective cohort. Values are presented as box
and whisker plots, where the boxes represent the interquartile range, the lines within the boxes
represent the median Larsen score, the whiskers represent the range from the smallest to the
largest score, and the circles represent outliers. 1 represents subjects who were RF and
anti-CCP (P  0.0001 versus subjects who were RF and anti-CCP, both in the total group and
in the group with erosions). 2 represents subjects who were RF and anti-CCP (P  versus
subjects who were RF and anti-CCP in the total group and P  0.0001 versus subjects who were
RF and anti-CCP in the group with erosions). 3 represents subjects who were RF and
anti-CCP (P  0.90 versus subjects who were RF and anti-CCP in the total group and P 
0.85 versus subjects who were RF and anti-CCP in the group with erosions). 4 represents
subjects who were RF and anti-CCP (referent).
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confounder.
DISCUSSION
We have shown that anti-CCP antibody status,
measured at presentation of IP, predicts both prevalent
erosions and development of erosions at 5 years. Fur-
thermore, anti-CCP antibody status is a better predictor
of future erosions than is RF, despite the fact that both
are correlated.
Anti-CCP antibody status has been proposed as a
new biomarker of disease severity, since it has been
found to be more sensitive than RF by all who have
published studies on this area. These antibodies have the
advantage that the status is stable over time as compared
with RF, which is known to vary (26). Questions remain,
however, regarding their usefulness in clinical practice,
particularly because the assay cost is higher than that of
RF, and it is unclear how much better than RF they are
at determining outcome. It is unclear whether both RF
and anti-CCP antibodies should be tested routinely in
patients or whether anti-CCP antibody testing should be
reserved for those who are RF negative.
Our study aimed to inform the debate and has
several advantages over previous investigations. First, we
used a primary care–based cohort of patients with
unselected IP, thus reflecting the mix of patients attend-
ing early arthritis clinics. Second, the study design re-
moves possible biases introduced when analysis is re-
stricted to RA patients, because erosions and RF (with
which anti-CCP antibodies are correlated) are both
criteria used to classify RA. Finally, the radiographs
were read blinded to anti-CCP status, removing the
possibility of observer bias. We tested radiologic ero-
sions as the primary outcome measure because they are
an objective, reliable, and standardized method of mea-
suring arthritis severity (27).
The results show that both RF and anti-CCP
antibody status are useful as predictors of adverse
outcome but that anti-CCP antibody status is stronger.
The group of patients who were anti-CCP but RF
had similar Larsen scores as the group negative for both
antibodies and significantly lower scores than the anti-
CCP,R F  group, although the small numbers in some
of the groups may have limited the robustness of these
conclusions. The LR for predicting erosions was higher
in the anti-CCP,R F  group, suggesting that one
possible strategy would be to test for anti-CCP antibod-
ies only in patients seronegative for RF.
It should be noted, however, that a significant
number of anti-CCP patients developed erosions at 5
years (27% of the prospective cohort). Larsen scores
were significantly lower in these patients compared with
anti-CCP subjects with erosions (median 16 [IQR
10–27] and 36 [IQR 20–48], respectively), suggesting
that anti-CCP antibodies may affect the extent or sever-
ity of radiologic damage as well as susceptibility to it.
However, the absence of anti-CCP antibodies cannot be
used to identify subjects who do not require treatment,
since even very low titers can be associated with the
development of erosions, particularly in RF subjects.
Conversely, 21% of patients positive for the
presence of anti-CCP antibodies had not developed
erosions at 5 years. This may reflect the benefit of
treatment if treatment was more likely to be provided to
anti-CCP patients, and indeed, this was found to be
the case. Thus, although the treating physician was
unaware of the antibody status, the presence of anti-
CCP antibodies was strongly associated with the likeli-
hood of receiving DMARDs or steroid therapy (OR 16.6
[95% CI 8.9–30.7]), presumably because of other mark-
ers of disease severity. The presence of RF was also
associated with receiving treatment, but to a lesser
degree (OR 5.2 [95% CI 3.4–7.8]). To address the issue
of possible confounding by treatment, we adjusted for
ever use of DMARDs or steroids at 5 years in the
analysis. Such an adjustment is inevitably quite crude
and almost certainly will not have accounted for all the
treatment effects. The results, after this adjustment,
showed that although the effects were attenuated, the
presence of either antibody remained strongly predictive
of the development of erosions.
In summary, ACPAs, as measured by anti-CCP
ELISAs, are strongly associated with both prevalent
erosions and the development of erosions at 5 years. In
this respect, it is a stronger predictor than RF, but
Table 4. Sensitivity, specificity, and likelihood ratios for predicting
erosions at baseline or at 5 years using baseline RF and anti-CCP
status either alone or in combination*
Sensitivity,
%
Specificity,
%
Likelihood
ratio
Cross-sectional cohort
All anti-CCP 45.5 75.2 1.8
Anti-CCP,R F  29.6 86.3 2.2
Anti-CCP,R F  77.5 38.7 1.3
All RF 33.1 76.7 1.4
RF, anti-CCP 13.6 88.0 1.1
RF, anti-CCP 56.4 42.4 1.0
Prospective cohort
All anti-CCP 54.7 89.4 5.2
Anti-CCP,i nR F  31.8 94.5 6.0
Anti-CCP,i nR F  87.8 61.5 2.3
All RF 40.9 85.2 2.4
RF, anti-CCP 11.0 89.1 1.0
RF, anti-CCP 65.7 42.3 1.1
* See Table 1 for definitions.
2934 BUKHARI ET ALbecause its detection contributes no additional value in
RF patients, testing could be restricted to seronegative
patients. Finally, despite the strong association of anti-
CCP antibodies with the presence, development, and
extent of erosions, knowledge of anti-CCP status alone is
still not a sufficiently accurate measure upon which to
base clinical treatment decisions, since a significant
proportion of anti-CCP patients develop erosions.
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